论文部分内容阅读
目的:探讨米非司酮改良剂量联合药物用于人工流产的临床分析。方法:将240例拟行人工流产的有终止妊娠需求的妊娠期妇女随机分为两组,各120例,其中研究组A采用改良剂量米非司酮、米索前列醇及甲氨蝶呤治疗;对照组B采取常规剂量米非前列酮、米索前列醇及甲氨蝶呤治疗,比较两组患者的临床效果。结果:研究组A组的完全流产率明显大于对照组B组的完全流产率(P<0.05)数据具有统计学意义;研究组A组的阴道出血量及阴道出血时间明显小于对照组B组(P<0.05)数据具有统计学意义。结论:改良后的米非司酮联合药物能够增大药物流产应用于人工流产的完全流产率,同时能够大大降低药物流产的阴道出血量及阴道出血时间,因此该改良后的联合药物治疗适合指导临床医生的药物流产,可以在临床上大力推广。
Objective: To investigate the clinical analysis of mifepristone modified dose combined with drugs for induced abortion. Methods: Two hundred and forty cases of pregnant women who had abortion requiring termination of pregnancy were randomly divided into two groups, 120 cases in each. The study group A was treated with modified doses of mifepristone, misoprostol and methotrexate ; The control group B to take the conventional dose of mifepristone, misoprostol and methotrexate treatment, the clinical effect of the two groups were compared. Results: The total abortion rate in study group A was significantly higher than that in control group B (P <0.05). The vaginal bleeding and vaginal bleeding time in study group A was significantly less than that in control group B P <0.05) The data have statistical significance. Conclusion: The modified mifepristone combination can increase the abortion rate of induced abortion and reduce the vaginal bleeding and vaginal bleeding time. Therefore, the improved combination therapy is suitable for guiding Clinicians medical abortion, can be vigorously promoted in the clinic.